The Filing Desk

Ardelyx vs Arcutis Biotherapeutics

Ardelyx ARDX · Arcutis Biotherapeutics ARQT · Pharmaceuticals

Ardelyx reported revenue of $407 million in fiscal 2025, about the same as Arcutis Biotherapeutics' $376 million in fiscal 2025. Ardelyx's revenue grew 22.1% in its latest year, and Arcutis Biotherapeutics' grew 91.3%. Ardelyx had an operating margin of -10.1%, against -3.2% at Arcutis Biotherapeutics. Free cash flow was −$44 million at Ardelyx and −$6 million at Arcutis Biotherapeutics.

Side by side

ArdelyxArcutis Biotherapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$407M$376M
Revenue growth22.1%91.3%
Revenue growth a year, last 5 years121.7%—
Gross margin90.3%90.2%
Operating margin−10.1%−3.2%
Net margin−15.1%−4.3%
Free cash flow−$44M−$6M
Free cash flow margin−10.8%−1.7%
Return on capital−36.1%−16.9%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.5%5.2%
Last close$3.09$28.26
P/E at the last close—134.6×
Insider trades, last 12 months—sold $12.2 million
Piotroski F-score2 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ArdelyxArcutis Biotherapeutics
Operating margin
Percent of revenue
ArdelyxArcutis Biotherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArdelyxArcutis Biotherapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ardelyx and Arcutis Biotherapeutics pages.